878 related articles for article (PubMed ID: 24573912)
1. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.
Yeaw J; Halinan S; Hines D; Delozier A; Perez M; Boye M; Boye KS; Blanchette CM
Appl Health Econ Health Policy; 2014 Apr; 12(2):219-30. PubMed ID: 24573912
[TBL] [Abstract][Full Text] [Related]
2. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.
Tunceli O; Wade R; Gu T; Bouchard JR; Aagren M; Luo W
Curr Med Res Opin; 2010 Aug; 26(8):1827-34. PubMed ID: 20491613
[TBL] [Abstract][Full Text] [Related]
3. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.
Pelletier EM; Smith PJ; Boye KS; Misurski DA; Tunis SL; Minshall ME
Appl Health Econ Health Policy; 2008; 6(2-3):103-12. PubMed ID: 19231904
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
5. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004.
van der Linden MW; Plat AW; Erkens JA; Emneus M; Herings RM
Value Health; 2009 Sep; 12(6):909-14. PubMed ID: 19508664
[TBL] [Abstract][Full Text] [Related]
6. Insulin therapy for diabetes mellitus: treatment regimens and associated costs.
Charbonnel B; Penfornis A; Varroud-Vial M; Kusnik-Joinville O; Detournay B
Diabetes Metab; 2012 Apr; 38(2):156-63. PubMed ID: 22172400
[TBL] [Abstract][Full Text] [Related]
7. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective.
St Charles M; Lynch P; Graham C; Minshall ME
Value Health; 2009; 12(5):674-86. PubMed ID: 19171006
[TBL] [Abstract][Full Text] [Related]
9. Health care utilization and costs in type 2 diabetes mellitus and their association with renal impairment.
Burke J; Kovacs B; Borton L; Sander S
Postgrad Med; 2012 Mar; 124(2):77-91. PubMed ID: 22437218
[TBL] [Abstract][Full Text] [Related]
10. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Bergeson JG; Worley K; Louder A; Ward M; Graham J
J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A;
Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523
[TBL] [Abstract][Full Text] [Related]
12. The burden of diabetes mellitus for medicare beneficiaries.
Costantino ME; Stacy JN; Song F; Xu Y; Bouchard JR
Popul Health Manag; 2014 Oct; 17(5):272-8. PubMed ID: 24865764
[TBL] [Abstract][Full Text] [Related]
13. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
[TBL] [Abstract][Full Text] [Related]
14. Costs of treatment and complications of adult type 1 diabetes.
Franciosi M; Lucisano G; Amoretti R; Capani F; Bruttomesso D; Di Bartolo P; Girelli A; Leonetti F; Morviducci L; Vitacolonna E; Nicolucci A
Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):606-11. PubMed ID: 22749531
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
[No Abstract] [Full Text] [Related]
16. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
[TBL] [Abstract][Full Text] [Related]
17. A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands.
de Groot S; Enters-Weijnen CF; Geelhoed-Duijvestijn PH; Kanters TA
BMJ Open; 2018 Mar; 8(3):e019864. PubMed ID: 29581204
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing the economic costs associated with type 1 and type 2 diabetes.
Dall TM; Mann SE; Zhang Y; Quick WW; Seifert RF; Martin J; Huang EA; Zhang S
Popul Health Manag; 2009 Apr; 12(2):103-10. PubMed ID: 19361253
[TBL] [Abstract][Full Text] [Related]
19. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities.
Candrilli SD; Meyers JL; Boye K; Bae JP
J Diabetes Complications; 2015; 29(4):529-33. PubMed ID: 25660136
[TBL] [Abstract][Full Text] [Related]
20. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
Tunis SL; Minshall ME
Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
